Literature DB >> 20413742

Overdiagnosis in cancer.

H Gilbert Welch1, William C Black.   

Abstract

This article summarizes the phenomenon of cancer overdiagnosis-the diagnosis of a "cancer" that would otherwise not go on to cause symptoms or death. We describe the two prerequisites for cancer overdiagnosis to occur: the existence of a silent disease reservoir and activities leading to its detection (particularly cancer screening). We estimated the magnitude of overdiagnosis from randomized trials: about 25% of mammographically detected breast cancers, 50% of chest x-ray and/or sputum-detected lung cancers, and 60% of prostate-specific antigen-detected prostate cancers. We also review data from observational studies and population-based cancer statistics suggesting overdiagnosis in computed tomography-detected lung cancer, neuroblastoma, thyroid cancer, melanoma, and kidney cancer. To address the problem, patients must be adequately informed of the nature and the magnitude of the trade-off involved with early cancer detection. Equally important, researchers need to work to develop better estimates of the magnitude of overdiagnosis and develop clinical strategies to help minimize it.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20413742     DOI: 10.1093/jnci/djq099

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  482 in total

Review 1.  Management of low (favourable)-risk prostate cancer.

Authors:  H Ballentine Carter
Journal:  BJU Int       Date:  2011-12       Impact factor: 5.588

2.  Optimization of PSA screening policies: a comparison of the patient and societal perspectives.

Authors:  Jingyu Zhang; Brian T Denton; Hari Balasubramanian; Nilay D Shah; Brant A Inman
Journal:  Med Decis Making       Date:  2011-09-20       Impact factor: 2.583

3.  Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis.

Authors:  Kathryn P Lowry; Janie M Lee; Chung Y Kong; Pamela M McMahon; Michael E Gilmore; Jessica E Cott Chubiz; Etta D Pisano; Constantine Gatsonis; Paula D Ryan; Elissa M Ozanne; G Scott Gazelle
Journal:  Cancer       Date:  2011-09-20       Impact factor: 6.860

4.  An investigation of the apparent breast cancer epidemic in France: screening and incidence trends in birth cohorts.

Authors:  Bernard Junod; Per-Henrik Zahl; Robert M Kaplan; Jørn Olsen; Sander Greenland
Journal:  BMC Cancer       Date:  2011-09-21       Impact factor: 4.430

5.  Disappearing breast cancers.

Authors:  S A Narod
Journal:  Curr Oncol       Date:  2012-04       Impact factor: 3.677

6.  Application of CT-PSF-based computer-simulated lung nodules for evaluating the accuracy of computer-aided volumetry.

Authors:  Ayumu Funaki; Masaki Ohkubo; Shinichi Wada; Kohei Murao; Toru Matsumoto; Shinji Niizuma
Journal:  Radiol Phys Technol       Date:  2012-03-25

Review 7.  An evolutionary perspective on field cancerization.

Authors:  Kit Curtius; Nicholas A Wright; Trevor A Graham
Journal:  Nat Rev Cancer       Date:  2017-12-08       Impact factor: 60.716

8.  Overdiagnosis in low-dose computed tomography screening for lung cancer.

Authors:  Edward F Patz; Paul Pinsky; Constantine Gatsonis; Jorean D Sicks; Barnett S Kramer; Martin C Tammemägi; Caroline Chiles; William C Black; Denise R Aberle
Journal:  JAMA Intern Med       Date:  2014-02-01       Impact factor: 21.873

9.  Diagnostic value of circulating microRNAs for lung cancer: a meta-analysis.

Authors:  Yongchun Shen; Tao Wang; Ting Yang; Qianjing Hu; Chun Wan; Lei Chen; Fuqiang Wen
Journal:  Genet Test Mol Biomarkers       Date:  2013-02-06

10.  Breast cancer screening initiation after turning 40 years of age within the PROSPR consortium.

Authors:  Elisabeth F Beaber; Anna N A Tosteson; Jennifer S Haas; Tracy Onega; Brian L Sprague; Donald L Weaver; Anne Marie McCarthy; Chyke A Doubeni; Virginia P Quinn; Celette Sugg Skinner; Ann G Zauber; William E Barlow
Journal:  Breast Cancer Res Treat       Date:  2016-09-24       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.